Phase 3 N=4 Comparing Buccal and Vaginal Misoprostol in Management of Early Pregnancy Loss
Spontaneous Abortion in First Trimester
Primary: Patient Enrollment — 2; 2 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=50 The Use of Cell Free Fetal DNA in the Maternal Blood in the Evaluation of Intrauterine Fetal Demise and Miscarriage
Circulating Cell Free Fetal DNA · Intrauterine Fetal Demise · Miscarriage
Primary: The Presence or Absence of Cell Free Fetal DNA in Maternal Blood in the Setting of a Failed Pregnancy. — 50 percentage of participants
Phase 3 N=153 Misoprostol for Treatment of Fetal Death at 14-28 Weeks of Pregnancy
Intrauterine Fetal Demise
Primary: Successful Expulsion of Fetus and Placenta Within 48 Hours — 60; 47 participants — p=<0.05
N/A N=349 Walking and Dietary Modification for Recurrent Early Miscarriages
Recurrent Miscarriage
Primary: Take-home Baby Rate — 152; 83 babies
Phase 3 N=300 Comparative Effectiveness of Pregnancy Failure Management Regimens
Spontaneous Abortion
Primary: Gestational Sac Expulsion With One Treatment Dose on Day 3 (Visit 2) and no Need for Additional Medical or Surgical Intervention Within 30 Days of Treatment. — 100; 124…
N/A N=251 Optimisation of the Management of Placental Delivery in Second Trimester Pregnancy Interruption
Placenta, Retained · Postpartum Hemorrhage
Primary: Placental Retention Rate — 26; 8; 24 participants — p=0.05
Phase 4 N=30 Simultaneous Mifepristone and Misoprostol Versus Misoprostol Alone for Induction of Labor of Nonviable Second Trimester Pregnancy: a Pilot Randomized Controlled Trial
Abortion, Second Trimester · PPROM · Rupture, Spontaneous
Primary: Delivery Within 12 Hours — 5; 5 Participants
Phase 4 N=211 Misoprostol 400 µg Versus 200 µg for Cervical Ripening in 1st Trimester Miscarriage
Miscarriage in First Trimester
Primary: Number of Participants Who Required Cervix Dilation at Initiation of the Manual Vacuum Aspiration — 4; 16; 102; 89 Participants — p=0.025
N/A N=77 Intravenous Immunoglobulin (IVIG) for Treatment of Unexplained Secondary Recurrent Miscarriage
Miscarriage, Recurrent · Abortion, Habitual
Primary: Number of Successful Pregnancies Defined as an Ongoing Pregnancy Over 20 Weeks Gestation, Per Number of Index Pregnancies — 16; 15 Successful pregnancies — p=<0.05
N/A N=452 Low Plasma Mannose Binding Lectin (p-MBL) Level is a Risk Factor for Recurrent Pregnancy Loss (RPL)
Recurrent Miscarriage · Spontaneous Abortion · Mannose-Binding Lectin Deficiency
Primary: Plasma MBL Level (ug/ml) — 717; 1717 ug/l — p=<0.001
Phase 2 N=3 Ulipristal Acetate for Use in Early Pregnancy Loss
Missed Abortion · Anembryonic Pregnancy · Non-Viable Pregnancy
Primary: Percentage of Participants Recruited to Study Protocol — 37.5 percentage of participants
N/A N=254 Media, Morphokinetics, and Mosaicism
Embryonic Mosaicism · Embryo Culture Media · Embryo Morphokinetics
Primary: Aneuploidy Rates — 56.1; 62.3 percentage of embryos — p=0.07
Phase 4 N=70 24-hour Mifepristone and Buccal Versus Mifepristone and Vaginal Misoprostol for Cervical Preparation for D&E
Abortion, Second Trimester
Primary: Procedure Time — 9.5; 9.9 minutes
Phase 4 N=100 Same-Day Mifepristone-Misoprostol Compared to Misoprostol Only for Surgical Abortion Cervical Preparation
Induced Abortion
Primary: Initial Cervical Dilation — 11.7; 10.9 mm
Phase 4 N=250 Pain Control In First Trimester Medical Abortion: A Randomized Trial
Pain
Primary: 11-point Visual Analog Scale for Pain — 7.1; 7.3 units on a scale
N/A N=51 The Role of a Semi-Quantitative Urine Pregnancy Test and Pregnancy Questionnaire After Uterine Evacuation for Undesired Pregnancy of Uncertain Location
Follow-up After Uterine Evacuation
Primary: Number of Women in Each Group Who Require a Return Visit to the Clinic for a Serum hCG Measurement, Ultrasound or Clinical Examination at One Week to Confirm Complete…
N/A N=500 Study of the Sensitivity of Manual vs Electric Aspiration to Detect Completed Early Abortion
Induced Abortion
Primary: Accurate Confirmation of Completed Abortion — 182; 164 participants — p=.13
N/A N=135 Fetal Fibronectin as a Predictor of Successful Induction of Mid-trimester Abortion
Medical; Abortion, Fetus
Primary: Cervicovaginal Fetal Fibronectin Level — 39.4 nanogram per milliliter
N/A N=22 MOMSonLINE2 ; A Pilot Study Testing Recruitment and Retention of Women of Color to an Online Support Group for Bereaved Mothers
Stillbirth · Grief · Infant Death
Primary: Percentage of Participants Approached for Enrollment Who Signed up for the Study — 22 Participants
Early Phase 1 N=170 Effect of Metformin on Early Pregnancy Loss in Pregnant Women With Polycystic Ovarian Syndrome
Polycystic Ovary Syndrome
Primary: Miscarriage Rate — 9; 35 participants
N/A N=50 Mifepristone Versus Laminaria Insertion for Cervical Preparation Prior to Surgical Abortion at 14-16 Weeks
Abortion
Primary: Time for Completion of Procedure — 8.0; 9.87 Minutes — p=0.05
N/A N=36 Rebif® Pregnancy Registry
Multiple Sclerosis
Primary: Spontaneous Abortion — 2; 0 Participants
Phase 3 N=50 Mifepristone Versus Osmotic Dilator Insertion for Cervical Preparation Prior to Surgical Abortion at 15-18 Weeks
Cervical Preparation
Primary: Length of Procedure — 14; 13.5 minutes
Phase 4 N=284 Uterotonic Prophylaxis Trial
Hemorrhage
Primary: Number of Participants With Excessive Bleeding as Determined by the Composite Outcome Criteria — 78; 75 Participants — p=0.5
N/A N=120 Insertion of an Intrauterine Device (IUD) After Medical Abortion
Intrauterine Device Expulsion · Medical Abortion · Induced Abortion
Primary: Percentage of Women With Expulsion of an Intrauterine Device (IUD) Placed After Medical Abortion. — 4 percentage of participants
N/A N=40 Misoprostol With Intrauterine Device Insertion
Contraception
Primary: The Ease of IUD Insertion as Rated by the Provider Using a 100mm Visual Analog Scale (VAS). — 24; 29 mm
N/A N=10 Blood Loss at the Time of First Trimester Surgical Abortion in Anticoagulated Women
Blood Loss
Primary: Volume of Intraoperative Blood Loss — 91.5; 52.2 milliliters
N/A N=125 Misoprostol Versus Dilapan-S for Cervical Preparation
Cervical Ripening
Primary: Cervical Dilation in Women Following Exposure to Either Ripening Agent — 32.1; 33.9 mm
Phase 2 N=69 Cabergoline for Lactation Inhibition After Early Second-Trimester Abortion or Pregnancy Loss
Lactation Suppressed
Primary: Number of Participants Reporting Breast Pain — 16; 30 Participants
Phase 2 N=374 Misoprostol Vaginal Insert (MVI) 100, 150, 200 mcg for Cervical Ripening and Induction of Labor
Cervical Ripening · Induction of Labor
Primary: Proportion of Women Delivering Vaginally — 63.75; 66.67; 76.00 percentage of participants — p=0.057